Skip to main content
Caplight Logo









Bright Angel Therapeutics

Bright Angel Therapeutics

Private
TorontoHealthcare & Life Scienceshttps://www.brightangeltherapeutics.com/

Last Round

Seed

Dec 3, 2019

Company Overview

Bright Angel Therapeutics is a biotechnology company that develops novel antifungal drugs to treat drug-resistant and life-threatening invasive fungal infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

antifungal therapeuticsdrug discoverysmall molecule inhibitorsbiotechnologycomputational drug discoveryin-silico drug discoveryfungal infectionsdrug resistancepre-clinical researchbiotech startuptherapeutic pipelinedrug developmentpharma R&DAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bright Angel Therapeutics Comparables

Compare Bright Angel Therapeutics with similar companies based on industry and business-model similarity.

Bright Angel Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rostra Therapeutics
82%
Brigid Bio Ltd
78%
Elion Therapeutics
76%

Bright Angel Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 3, 2019
SeedDec 21, 2017

Bright Angel Therapeutics Investors

Notable investors and investment history

Bright Angel Therapeutics investors
InvestorRounds
Viva BioInnovatorSeed
Lumira VenturesSeed
TIAPSeed
adMare BioInnovationsSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 4, 2025

    Monthly visitors grew 70% MoM.

  • Oct 30, 2024

    Monthly visitors increased 139% MoM.

Bright Angel Therapeutics Filings

Explore SEC and related filing metadata, where available.

Bright Angel Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Bright Angel Therapeutics's valuation, stock price, and market status.

Is Bright Angel Therapeutics a public or private company?

Bright Angel Therapeutics is a private company.

What is the current stock price of Bright Angel Therapeutics?

Bright Angel Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Bright Angel Therapeutics worth (valuation)?

Valuation information for Bright Angel Therapeutics is not publicly available.

Can I buy Bright Angel Therapeutics stock?

Bright Angel Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Bright Angel Therapeutics's last funding round?

Bright Angel Therapeutics's most recent funding round was Seed on December 3, 2019.

Who are the main investors in Bright Angel Therapeutics?

Key investors in Bright Angel Therapeutics include Viva BioInnovator, Lumira Ventures, TIAP, adMare BioInnovations.

Will Bright Angel Therapeutics IPO soon?

No public IPO plans have been announced for Bright Angel Therapeutics.

How can I track Bright Angel Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Bright Angel Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersToronto
Employee Range2
Year Founded2017
Last FundingDec 3, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?